Autologous T-Cells Expressing a Second Generation CAR for Treatment of T-Cell Malignancies Expressing CD5 Antigen
Plain-language summary
This Phase 1 trial is comparing Autologous CD5.CAR/28zeta CAR T cells and Allogeneic CD5.CAR/28zeta CAR T cells against other options for people whose a type of T-cell lymphoma called AITL has come back or has not responded to previous treatment. Patients are randomly assigned to different treatment groups to see which approach works best. It is available at 2 US locations.
Who can join (key eligibility)
- Lymphoma came back or did not respond to prior treatment
- See full trial listing for complete eligibility
Final eligibility is determined by the trial team. This list is a starting point only.
What's being tested
Autologous CD5.CAR/28zeta CAR T cells (GENETIC): Three dose levels will be evaluated: Dose level one: 1×10\^7 cells/m2 Dose level two: 5×10\^7 cells/m2 Dose level three: 1×10\^8 cells/m2 | Allogeneic CD5.CAR/28zeta CAR T cells (GENETIC): Three dose levels will be evaluated: Dose level one: 1×10\^7 cells/m2 Dose level two: 5×10\^7 cells/m2 Dose level three: 1×10\^8 cells/m2
- Drugs / treatments
- Autologous CD5.CAR/28zeta CAR T cells, Allogeneic CD5.CAR/28zeta CAR T cells
- Treatment length
- Ask the trial team for details
- Visit frequency
- Ask the trial team for details